

Respiratory Requisition

Date Specimen Collected: _____ Time Specimen Collected: _____

Laboratory Use Only

Accession Number _____ Date Received _____ Time Received _____

Practice Name _____ Practice ID _____ **Practice Contact Information**
Ordering Physicians ☐ _____ Address _____
☐ _____ City, State, Zip _____
☐ _____ Phone _____
☐ _____ Fax _____

Patient and Insurance Information

(Currently Not Accepting Medicaid or Managed Medicaid Plans - Contract Pending)

First Name _____ Last Name _____ Middle Initial _____ Gender* _____
Address Line 1 _____ Address Line 2 _____ City _____ State _____ Zip _____
DOB _____ Cell/Home Phone* _____ Email _____
Gender Identity* _____ Race* _____ Ethnicity* _____ Sexual Orientation* _____

Insured's Name _____ Relationship to Patient _____ Social Security # _____
Home Phone _____ Cell Phone _____ DOB _____ Gender _____
Primary Insurance _____ Secondary Insurance _____
Group # _____ ID# _____ Group # _____ ID# _____
Address _____ Address _____
City _____ State _____ Zip _____ City _____ State _____ Zip _____

Respiratory Test Panels

Nasal Swab OR Nasopharyngeal Swab:

- ☐ Genesis Respiratory Pathogen Panel (Including COVID-19) (UTM Swab) (See back for details.)
☐ COVID-19 + Influenza A & B, and RSV Panel (UTM Swab)
☐ _____

Throat Swab:

- ☐ Group A Streptococcus
(Liquid Amies/eSwab)

ICD-10 Codes

- ☐ R05.1 Acute cough < 3 weeks
☐ R05.2 Subacute cough > 3 weeks
☐ R06.02 Shortness of breath
☐ R06.03 Acute respiratory distress
☐ R06.2 Wheezing
☐ R07.1 Chest pain on breathing
☐ R43.9 Unspecified disturbances of smell and taste
☐ R50.9 Fever unspecified
☐ R53.1 Weakness
☐ R68.83 Chills (without fever)
☐ J00 Acute nasopharyngitis (common cold)
☐ J02.9 Acute pharyngitis, unspecified
☐ J04.0 Acute laryngitis
☐ J06.9 Acute upper respiratory infection, unspecified
☐ J12.89 Other viral pneumonia
☐ J18.8 Other pneumonia, unspecified organism
☐ J20.8 Acute bronchitis due to other specified organisms
☐ J22 Unspecified acute lower respiratory infection
☐ Z20.828 Exposure to other viral communicable diseases

Immunodeficiency ICD-10 Codes

- ☐ D84.821 Immunodeficiency due to drugs
☐ D81.9 Combined immunodeficiency, unspecified
☐ D83.8 Other common variable immunodeficiencies
☐ D83.9 Common variable immunodeficiency, unspecified
☐ D84.89 Other immunodeficiencies
☐ D84.9 Immunodeficiency, unspecified
☐ D81.89 Other combined immunodeficiencies
☐ _____
☐ _____

This test is medically necessary for the diagnosis or detection of a disease, illness, impairment, symptom, syndrome or disorder. The results will determine my patient's medical management and treatment decisions. The person listed as the ordering provider is authorized by law to order the test(s) requested herein.

Patient Authorization: I hereby authorize Genesis Laboratory Management to submit a claim to my insurance company for above services and appeal if necessary on my behalf.

Signature of Physician or Other Authorized NPI Provider (REQUIRED) _____ Date _____

Signature of Patient (REQUIRED) _____

Date _____

Accessioner Initials 1 _____ 2 _____

Genesis Respiratory Pathogen Panel

Viruses

Adenovirus
COVID-19 (SARS-CoV-2)
Rhinovirus
Influenza A virus/Influenza B virus Pan
Respiratory syncytial virus

Bacteria

Bordetella pertussis
Bordetella parapertussis
Chlamydia pneumoniae
Mycoplasma pneumoniae
Legionella pneumophila

COVID-19 + Influenza A & B, and RSV Panel

COVID-19 (SARS-CoV-2)
Influenza A
Influenza B
Respiratory Syncytial Virus (RSV)

Group A Streptococcus

Streptococcus pyogenes

COVID-19

Information about COVID-19 (SARS-CoV-2 PCR Assay)

PLEASE NOTE: Testing was performed using the TaqPath COVID-19 Combo Kit and/or Panther Fusion® SARS-CoV-2 Assay Kit by real-time (RT) PCR. Positive results do not rule out co-infection with organisms not included in the TaqPath COVID-19 Combo Kit and/or Panther Fusion® SARS-CoV-2 Assay Kit by real-time (RT) PCR. The agent detected may not be the definite cause of this disease. This assay is for in vitro diagnostic use under the FDA Emergency Use Authorization (EUA). This test is only authorized for the duration of time of the declaration and for the detection of SARSCoV-2 RNA virus and/or diagnosis of COVID-19 infection under section 564 (b)(1) of the act, 21 U.S.C.360bbb-3(b)(1) unless the authorization is terminated or revoked sooner.

A Positive result indicates the presence of SARS-CoV-2 RNA but does not exclude bacterial infection and/or coinfection with other viruses. The agent detected may not be the definitive cause of disease. This result should be combined with clinical observation, patient history, and epidemiological information for patient management decisions.

Negative results do not preclude SARS-CoV-2 infection and should not be used as the sole basis for treatment and other patient management decisions. Negative results must be used in conjunction with clinical observation, patient history, and epidemiological information for patient management decisions.